Role of Chemokine (C-X-C Motif) Ligand 10 (CXCL10) in Renal Diseases

被引：53

作者：

Gao, Jie ^{[1
,2
]}

Wu, Lingling ^{[1
]}

Wang, Siyang ^{[1
]}

Chen, Xiangmei ^{[1
]}

机构：

[1] Natl Clin Res Ctr Kidney Dis, Beijing Key Lab Kidney Dis, Chinese PLA Inst Nephrol, Dept Nephrol,Chinese PLA Gen Hosp,State Key Lab K, Fuxing Rd 28, Beijing 100853, Peoples R China

[2] Shandong Univ, Dept Nephrol, Shandong Prov Hosp, Jingwu Rd 324, Jinan 250000, Peoples R China

来源：

MEDIATORS OF INFLAMMATION | 2020年 / 2020卷

基金：

中国国家自然科学基金;

关键词：

INTERFERON-INDUCIBLE PROTEIN-10; HUMAN MESANGIAL CELLS; DOUBLE-STRANDED-RNA; REGULATORY T-CELLS; MONOCYTE CHEMOATTRACTANT PROTEIN-1; TOLL-LIKE RECEPTOR-3; ACUTE KIDNEY INJURY; SERUM-LEVELS; IFN-GAMMA; CXCR3; LIGANDS;

D O I：

10.1155/2020/6194864

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Chemokine C-X-C ligand 10 (CXCL10), also known as interferon-gamma-inducible protein 10 (IP-10), exerts biological function mainly through binding to its specific receptor, CXCR3. Studies have shown that renal resident mesangial cells, renal tubular epithelial cells, podocytes, endothelial cells, and infiltrating inflammatory cells express CXCL10 and CXCR3 under inflammatory conditions. In the last few years, strong experimental and clinical evidence has indicated that CXCL10 is involved in the development of renal diseases through the chemoattraction of inflammatory cells and facilitation of cell growth and angiostatic effects. In addition, CXCL10 has been shown to be a significant biomarker of disease severity, and it can be used as a prognostic indicator for a variety of renal diseases, such as renal allograft dysfunction and lupus nephritis. In this review, we summarize the structures and biological functions of CXCL10 and CXCR3, focusing on the important role of CXCL10 in the pathogenesis of kidney disease, and provide a theoretical basis for CXCL10 as a potential biomarker and therapeutic target in human kidney disease.

引用

页数：16

共 147 条

[91] Chemoattractant mechanism of Th1 cells in class III and IV lupus nephritis [J].

Morimoto, Shinji ;

Tokano, Yoshiaki ;

Nakano, Souichiro ;

Watanabe, Takashi ;

Tamayama, Yoshihiro ;

Mitsuo, Akiko ;

Suzuki, Jun ;

Kaneko, Hiroshi ;

Sekigawa, Iwao ;

Takasaki, Yoshinari .

AUTOIMMUNITY, 2009, 42 (02) :143-149

[92] Podocyte injuries exacerbate mesangial proliferative glomerulonephritis [J].

Morioka, Y ;

Koike, H ;

Ikezumi, Y ;

Ito, Y ;

Oyanagi, A ;

Gejyo, F ;

Shimizu, F ;

Kawachi, H .

KIDNEY INTERNATIONAL, 2001, 60 (06) :2192-2204

[93] CXCR3 Promotes the Production of IgG1 Autoantibodies but Is Not Essential for the Development of Lupus Nephritis in NZB/NZW Mice [J].

Moser, Katrin ;

Kalies, Kathrin ;

Szyska, Martin ;

Humrich, Jens Y. ;

Amann, Kerstin ;

Manz, Rudolf A. .

ARTHRITIS AND RHEUMATISM, 2012, 64 (04) :1237-1246

[94] Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial [J].

Motzer, Robert J. ;

Porta, Camillo ;

Vogelzang, Nicholas J. ;

Sternberg, Cora N. ;

Szczylik, Cezary ;

Zolnierek, Jakub ;

Kollmannsberger, Christian ;

Rha, Sun Young ;

Bjarnason, Georg A. ;

Melichar, Bohuslav ;

De Giorgi, Ugo ;

Gruenwald, Viktor ;

Davis, Ian D. ;

Lee, Jae-Lyun ;

Esteban, Emilio ;

Urbanowitz, Gladys ;

Cai, Can ;

Squires, Matthew ;

Marker, Mahtab ;

Shi, Michael M. ;

Escudier, Bernard .

LANCET ONCOLOGY, 2014, 15 (03) :286-296

[95] Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial [J].

Motzer, Robert J. ;

Escudier, Bernard ;

Tomczak, Piotr ;

Hutson, Thomas E. ;

Michaelson, M. Dror ;

Negrier, Sylvie ;

Oudard, Stephane ;

Gore, Martin E. ;

Tarazi, Jamal ;

Hariharan, Subramanian ;

Chen, Connie ;

Rosbrook, Brad ;

Kim, Sinil ;

Rini, Brian I. .

LANCET ONCOLOGY, 2013, 14 (06) :552-562

[96] Blockade of IP-10/CXCR3 promotes progressive renal fibrosis [J].

Nakaya, Izaya ;

Wada, Takashi ;

Furuichi, Kengo ;

Sakai, Norihiko ;

Kitagawa, Kiyoki ;

Yokoyama, Hitoshi ;

Ishida, Yuko ;

Kondo, Toshikazu ;

Sugaya, Takeshi ;

Kawachi, Hiroshi ;

Shimizu, Fujio ;

Narumi, Shosaku ;

Haino, Makoto ;

Gerard, Craig ;

Matsushima, Kouji ;

Kaneko, Shuichi .

NEPHRON EXPERIMENTAL NEPHROLOGY, 2007, 107 (01) :E12-E21

[97] Serum levels of IFN-inducible protein-10 relating to the activity of systemic lupus erythematosus [J].

Narumi, S ;

Takeuchi, T ;

Kobayashi, Y ;

Konishi, K .

CYTOKINE, 2000, 12 (10) :1561-1565

[98] T Lymphocyte Recruitment into Renal Cell Carcinoma Tissue: A Role for Chemokine Receptors CXCR3, CXCR6, CCR5, and CCR6 [J].

Oldham, Kimberley A. ;

Parsonage, Greg ;

Bhatt, Rupesh I. ;

Wallace, D. Michael A. ;

Deshmukh, Nayneeta ;

Chaudhri, Shalini ;

Adams, David H. ;

Lee, Steven P. .

EUROPEAN UROLOGY, 2012, 61 (02) :385-394

[99] CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis [J].

Pan, JD ;

Burdick, MD ;

Belperio, JA ;

Xue, YY ;

Gerard, C ;

Sharma, S ;

Dubinett, SM ;

Strieter, RM .

JOURNAL OF IMMUNOLOGY, 2006, 176 (03) :1456-1464

[100] Compartment-specific expression and function of the chemokine IP-10/CXCL10 in a model of renal endothelial microvascular injury [J].

Panzer, Ulf ;

Steinmetz, Oliver M. ;

Reinking, Ruediger R. ;

Meyer, Tobias N. ;

Fehr, Susanne ;

Schneider, Andre ;

Zahner, Gunther ;

Wolf, Gunter ;

Helmchen, Udo ;

Schaerli, Patrick ;

Stahl, Rolf A. K. ;

Thaiss, Friedrich .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (02) :454-464

← 5 6 7 8 9 10 11 12 13 14 →